Urgent Clinical Commissioning Policy Statement: Natalizumab-induced Progressive Multifocal Leukoencephalopathy in relation to Immune Reconstitution Inflammatory Syndrome in Multiple Sclerosis (all ages)

Document first published:
Page updated:
Topic:
,
Publication type:

This clinical commissioning policy statement is an interim commissioning position pending the formation of a Clinical Policy.

Document

Urgent Clinical Commissioning Policy Statement: Natalizumab-induced Progressive Multifocal Leukoencephalopathy in relation to Immune Reconstitution Inflammatory Syndrome in Multiple Sclerosis (all ages)

Urgent Clinical Commissioning Policy Statement: Natalizumab-induced Progressive Multifocal Leukoencephalopathy in relation to Immune Reconstitution Inflammatory Syndrome in Multiple Sclerosis (all ages)

  • PDF
  • 74 KB
  • 5 pages